A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma

Br J Haematol. 2020 Mar;188(6):e94-e98. doi: 10.1111/bjh.16378. Epub 2020 Feb 14.
No abstract available

Keywords: carfilzomib; ibrutinib; mantle cell lymphoma.

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy*
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Oligopeptides / pharmacology
  • Oligopeptides / therapeutic use*
  • Piperidines
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*

Substances

  • Oligopeptides
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • carfilzomib
  • Adenine